Roles of the E3 Ubiquitin Ligase TRIM47 in Inflammation, Organ Injury, and Cancer

ABSTRACT

TRIM47 is an emerging E3 ubiquitin ligase of the tripartite motif family that has been increasingly implicated in inflammation, tissue injury, fibrosis, and cancer. Rather than acting as a disease‐specific factor, TRIM47 appears to function as a context‐dependent organizer of ubiquitin signaling, in which substrate selection and ubiquitin‐chain topology shape distinct pathological outputs. Through K48‐linked ubiquitination, TRIM47 promotes degradation of inhibitory or protective proteins, including CYLD, SIRT1, PPM1A, FBP1, CDO1, p53, Smad4, and XAF1, whereas through K63‐linked ubiquitination it enhances signaling activity of mediators such as NEMO and PARP1. These substrate‐ and chain‐dependent actions converge on a limited set of recurrent mechanisms, including inflammatory amplification, profibrotic remodeling, metabolic reprogramming, ferroptosis resistance, apoptosis escape, and DNA repair rewiring. This framework helps explain the repeated involvement of TRIM47 across innate immune dysregulation, organ injury, fibrogenesis, tumor progression, and treatment response. Notably, TRIM47 may also act as a double‐edged regulator of therapy, promoting resistance to platinum‐, taxane‐, and endocrine‐based treatments while potentially increasing vulnerability to PARP inhibition in selected homologous recombination‐deficient settings. Although these observations support TRIM47 as a promising biomarker and therapeutic target, major gaps remain, including incomplete substrate and ubiquitin‐site mapping, limited cell type‐specific in vivo validation, insufficient structural and interactome data, and the lack of TRIM47‐selective inhibitors. A mechanism‐centered understanding of TRIM47 will be essential for improving disease stratification and developing rational TRIM47‐directed therapies.

TRIM47 orchestrates ubiquitin‐dependent signaling across inflammation, fibrosis, and cancer progression. Schematic summary of how TRIM47 integrates diverse upstream stressors into recurrent pathological outputs through substrate selection and ubiquitin‐chain topology. Left, representative upstream inducers and disease contexts that promote TRIM47 upregulation, including inflammatory cytokines (e.g., TNF‐α), hypoxia/ischemia–reperfusion, toxic or metabolic stress, oncogenic signaling and METTL3‐dependent m^6A stabilization. Center, “TRIM47 core ubiquitin logic” depicting two dominant chain outcomes: K48‐linked ubiquitination, promoting proteasomal degradation and loss of protective/anti‐pathogenic factors; and K63‐linked ubiquitination, amplifying signaling and pathway activation. Right, substrate classes highlighted in this review, including inhibitory brakes (CYLD, SIRT1, PPM1A), metabolic regulators (FBP1, CDO1), tumor suppressors/apoptosis regulators (p53, Smad4, XAF1), signaling/stress regulators (NEMO, NF90, IκBα) and DNA repair factors (BRCA1, PARP1). These chain‐ and substrate‐dependent actions converge on shared functional outputs, including inflammatory amplification (NF‐κB/inflammasome priming), cell injury and inflammatory cell death (including pyroptosis), fibrotic remodeling, metabolic rewiring with ferroptosis resistance, apoptosis escape, DNA‐repair remodeling, immune/microenvironmental modulation and context‐dependent therapy resistance or vulnerability. Together, these modules position TRIM47 as a pathway‐rewiring E3 ligase operating along a disease continuum from inflammation and tissue injury to fibrosis, cancer progression and treatment response.

1. Introduction

Tripartite motif (TRIM) proteins constitute a large family of E3 ubiquitin ligases characterized by a conserved N‐terminal RBCC module—comprising a RING finger, one or two B‐boxes, and a coiled‐coil domain—followed by a variable C‐terminal region often containing a PRY/SPRY (B30.2) domain that mediates substrate recognition. Through this modular architecture, TRIM proteins orchestrate the ubiquitination of diverse substrates and thereby exert broad control over innate immunity, inflammatory signaling, metabolic homeostasis, and tumor biology [1, 2]. A growing body of work has delineated roles for multiple TRIM members in antiviral responses, NF‐κB and interferon pathways, autophagy, and oncogenic signaling, and disease‐focused reviews have begun to frame TRIMs as nodal regulators in urological cancers and hormone‐dependent malignancies [3, 4]. However, within this family, individual TRIM proteins may display highly context‐specific substrates and functions that are not captured by generalized TRIM overviews.

TRIM47, encoded at the 17q25 locus and linked by genome‐wide association studies to cerebral small vessel disease and white matter hyperintensities, has emerged from relative obscurity to a recurrent signal across disparate disease settings. Structurally, TRIM47 conforms to the canonical RBCC–SPRY organization, but its expression pattern and substrate spectrum suggest a preferential engagement with stress and damage pathways [5]. Experimental studies demonstrate that TRIM47 is upregulated in models of nonalcoholic steatohepatitis, pulmonary fibrosis, toxicant‐induced immune kidney injury, cerebral ischemia–reperfusion, and anesthetic‐related neurotoxicity, where it promotes inflammatory signaling, endothelial or parenchymal cell injury, and fibrogenesis. In parallel, TRIM47 is consistently overexpressed in a wide range of solid tumors—including renal, hepatocellular, colorectal, gastric, pancreatic, lung, breast, ovarian, gallbladder, head and neck cancers, as well as glioma and prostate cancer—where it supports proliferation, survival, invasion, metabolic reprogramming, and therapy resistance [4, 6].

Mechanistically, TRIM47 has been shown to ubiquitinate and destabilize key negative regulators of inflammation and stress responses, such as CYLD, SIRT1, and PPM1A, as well as metabolic and tumor suppressor proteins including FBP1, CDO1, Smad4, p53, XAF1, and NF90. It also catalyzes non‐degradative K63‐linked ubiquitination of signaling intermediates such as NEMO, PARP1, and vimentin, thereby amplifying NF‐κB activation, DNA damage responses, and cytoskeletal dynamics. Beyond reductionist models, multi‐omics studies now implicate TRIM47 in E3 ligase–based prognostic signatures for idiopathic pulmonary fibrosis, multiple myeloma, uveal melanoma, and hepatocellular carcinoma, and in post‐translational modification networks associated with Alzheimer's disease. Yet despite this rapidly expanding and increasingly interconnected evidence base, data on TRIM47 remain highly fragmented—typically embedded within disease‐centric reports—and no comprehensive synthesis currently integrates its roles across inflammation, organ damage, and cancer [6, 7].

However, the current literature on TRIM47 remains largely fragmented and disease‐centered, which obscures the possibility that many apparently distinct phenotypes may arise from a limited set of recurring ubiquitin‐dependent mechanisms. Rather than viewing TRIM47 simply as a factor reported in multiple pathological settings, we propose that it should be understood as a context‐dependent organizer of ubiquitin signaling, in which substrate choice and ubiquitin‐chain topology shape shared pathogenic outputs across inflammation, tissue injury, fibrosis, cancer progression, and treatment response. In this framework, TRIM47‐dependent regulation of inhibitory checkpoints, metabolic enzymes, tumor suppressors, and DNA repair factors converges on a limited number of functional modules, including inflammatory amplification, profibrotic remodeling, metabolic rewiring, ferroptosis resistance, apoptosis escape, and therapeutic vulnerability. We therefore synthesize the available evidence through a mechanism‐centered perspective rather than a purely disease‐by‐disease description, with emphasis on substrate classes, signaling logic, translational implications, and the major unresolved questions that define the next stage of TRIM47 research.

2. TRIM47 Biology: Regulation, Substrate Logic, and Human Multi‐Omics Support

2.1. Structural Basis and Genomic Context

TRIM47 is encoded on chromosome 17q25 and exhibits the canonical TRIM family RBCC–SPRY architecture, comprising an N‐terminal RING finger domain, one or two B‐boxes, a coiled‐coil region, and a C‐terminal PRY/SPRY (B30.2) domain. This modular structure underpins its E3 ubiquitin ligase function: the RING domain mediates ubiquitin transfer, the coiled‐coil region supports oligomerization, and the PRY/SPRY domain contributes to substrate recognition. Although high‐resolution structural data are lacking, homology and mutational studies indicate that TRIM47 activity and substrate specificity depend on this conserved domain organization [4, 8, 9].

Beyond its structural organization, the genomic context of TRIM47 also suggests potential relevance to human disease. TRIM47 lies in close proximity to TRIM65 within the 17q25 locus, a region repeatedly implicated by genome‐wide association studies of cerebral small vessel disease and white matter hyperintensities [9]. Although these association signals do not uniquely resolve TRIM47 from neighboring genes, fine‐mapping and expression‐based analyses consistently point to this region as a susceptibility locus for white matter lesions and related microangiopathic phenotypes. Thus, both its conserved structural organization and its genomic positioning support the view that TRIM47 is a biologically plausible mediator of context‐dependent disease processes.

2.2. Induction and Expression in Stressed and Diseased Tissues

TRIM47 is detected at low to moderate abundance in normal tissues but is recurrently induced in inflamed, injured, fibrotic, and malignant contexts [10, 11, 12]. Disease‐oriented studies consistently report marked upregulation of TRIM47 in pathological settings. In nonalcoholic steatohepatitis, pulmonary fibrosis, trichloroethylene‐induced immune kidney injury, cerebral ischemia–reperfusion and sevoflurane‐induced neurotoxicity, TRIM47 expression is induced in parenchymal and/or endothelial cells in parallel with inflammatory and fibrotic responses [12, 13, 14, 15]. In cancers, TRIM47 is overexpressed across a broad spectrum of entities, including renal cell carcinoma, hepatocellular carcinoma, colorectal and gastric cancers, pancreatic and gallbladder carcinomas, non–small‐cell lung cancer, breast, ovarian and prostate cancers, gliomas and head and neck squamous cell carcinomas, where it often correlates with higher stage, metastasis and poor prognosis [16, 17]. These convergent observations suggest that TRIM47 is a stress‐responsive E3 ligase preferentially engaged in inflamed, damaged or transformed tissues.

Upstream regulatory mechanisms of TRIM47 are only partially understood. Experimental data indicate that inflammatory cytokines, particularly tumor necrosis factor‐α, can induce TRIM47 in endothelial and renal cells, consistent with an NF‐κB–driven transcriptional program [15]. In several tumor models, TRIM47 expression associates with STAT3 and hypoxia‐related signatures, implying regulation by oncogenic and stress‐activated transcription factors, although direct promoter binding has rarely been demonstrated [18]. Post‐transcriptionally, m6A RNA methylation by METTL3 stabilizes TRIM47 mRNA in paclitaxel‐resistant ovarian cancer cells, establishing an epitranscriptomic layer of control that links chemotherapy exposure to sustained TRIM47 overexpression [19]. Additional regulation by microRNAs, long noncoding RNAs, or chromatin modifications has been suggested in isolated reports but remains largely unexplored.

Subcellular localization studies show that TRIM47 is predominantly cytoplasmic under basal conditions, in keeping with its role in ubiquitinating cytosolic substrates and signaling adaptors, but nuclear pools have been observed in some tumor cells and may be relevant for DNA damage response functions.

2.3. Substrate Classes and Ubiquitin‐Chain Logic

Functionally, TRIM47 should be understood less as a substrate‐by‐substrate enzyme list and more as a context‐dependent E3 ligase whose biological output depends on two linked variables: substrate class and ubiquitin‐chain topology. In the liver, TRIM47 targets the deubiquitinase CYLD for K48‐linked ubiquitination and degradation, thereby relieving inhibition of TAK1 and promoting JNK/p38 activation in steatohepatitis [20]. In toxicant‐induced kidney injury and pulmonary fibrosis, TRIM47 similarly ubiquitinates and destabilizes the deacetylase SIRT1 and the phosphatase PPM1A, respectively, amplifying HMGB1 signaling and TGF‐β/SMAD3 and NF‐κB/NLRP3 pathways [14, 15]. In cancer, TRIM47 mediates K48‐linked ubiquitination of metabolic enzymes such as FBP1 and CDO1, suppressing gluconeogenic and ferroptosis‐promoting functions to facilitate aerobic glycolysis and redox homeostasis [17, 21]. In renal and prostate cancers, TRIM47 either directly targets p53 or enhances MDM2‐dependent p53 inactivation, while in colorectal and head and neck cancers it promotes degradation of Smad4 and XAF1, further disarming canonical tumor suppressor pathways [22, 23, 24]. The expanding TRIM47 substrate repertoire and its disease‐contextual functional consequences are organized in Table 1.

TABLE 1.

Validated And Proposed Trim47 Substrates And Downstream Pathways.

Substrate	Ubiquitin linkage	Functional category	Major downstream pathway(s)	Representative disease/model	Functional consequence of TRIM47 modification	References
CYLD	K48	DUB	TAK1–JNK/p38; NF‐κB	Gastric cancer; NASH	CYLD↓ → sustained TAK1 K63‐Ub → amplified inflammation/fibrosis	[20, 25]
SIRT1	K48	Deacetylase	HMGB1acetylation; NF‐κB	Immune kidney injury	SIRT1 ↓ → HMGB1 acetylation and release → podocyte injury and inflammation	[15]
PPM1A	K48	Phosphatase	TGF‐β/SMAD3; NF‐κB/NLRP3	PF	PPM1A↓ → enhanced SMAD3 and inflammasome signaling	[14]
FBP1	K48	Metabolic enzyme	Glucose metabolism	Pancreatic cancer; prostate cancer	FBP1↓ → increased glycolysis → tumor growth	[17, 26]
CDO1	K48	Metabolic enzyme	Ferroptosis	HCC	CDO1 ↓ → GSH maintenance → ferroptosis suppression	[21]
p53	K48	Tumor suppressor	Cell‐cycle arrest; apoptosis	RCC; prostate cancer	p53 ↓ → enhanced proliferation and invasion	[22, 27]
Smad4	K48	Tumor suppressor/mediator	TGF‐β signaling	Colorectal cancer; glioma	Smad4 ↓ → pro‐invasive TGF‐β reprogramming, angiogenesis	[23, 28]
XAF1	K48	Pro‐apoptotic factor	Caspase activation	Head and neck squamous cell carcinoma	XAF1 ↓ → apoptosis resistance, malignant progression	[24]
NEMO	K63	NF‐κB adaptor	Canonical NF‐κB, NLRP3 inflammasome	Airway epithelial inflammation	NEMO↑ → NF‐κB activation → pyroptosis and cytokine release	[29]
IκBα	NA	NF‐κB inhibitor	NF‐κB	Gastric cancer	IκBα↓ → NF‐κB activation	[25]
NF90	K48	RNA‐binding protein	Antiviral innate immunity; stress granules	Tim‐3–mediated antiviral responses	NF90↓ → impaired antiviral responses, reduced stress granules	[30]
BRCA1	K48	DNA repair factor	HR	Triple‐negative breast cancer	BRCA1↓ dysfunction → HRD → increased PARPi sensitivity, genomic instability	[31]
PARP1	K63	DNA repair enzyme	PARP‐dependent single‐strand break repair	Gallbladder cancer	PARP1 activation and dependence → tumor progression, PARPi vulnerability	[32]

Abbreviations: DUB, deubiquitinase; HCC, hepatocellular carcinoma; HR, homologous recombination; NASH, non‐alcoholic steatohepatitis dysfunction; PF, pulmonary fibrosis; RCC, renal cell carcinoma.

In contrast, TRIM47 also assembles non‐degradative K63‐linked ubiquitin chains on signaling intermediates to potentiate their activity. In airway epithelial cells exposed to house dust mite, TRIM47 catalyzes K63‐linked ubiquitination of NEMO, strengthening IKK activation, NF‐κB nuclear translocation and downstream NLRP3 inflammasome–dependent pyroptosis [29]. In gallbladder cancer, TRIM47 enhances K63‐linked ubiquitination of PARP1, reinforcing DNA damage signaling and malignancy, and in cytoskeletal remodeling it modifies vimentin to promote migration and invasion [32]. Additional evidence suggests that TRIM47 can modulate IκBα stability and NF90 turnover, thereby influencing NF‐κB dynamics and antiviral stress granule formation, although the precise chain types and ubiquitination sites are less well‐defined [30, 33]. Whether TRIM47 undergoes significant auto‐ubiquitination that regulates its own stability and activity, a common regulatory feature among TRIMs, remains to be systematically investigated. Thus, the emerging substrate repertoire suggests that TRIM47 repeatedly rewires a limited set of signaling modules rather than acting through unrelated disease‐specific mechanisms.

2.4. Human Genetic and Multi‐Omics Evidence: Recurrence Without Full Mechanistic Resolution

Beyond positional genetics, transcriptomic and proteomic signatures have further linked TRIM47 to disease risk and outcome in multiple organ systems. In hepatocellular carcinoma, TRIM47 emerges as part of TRIM family– or ubiquitin–proteasome–based gene panels that stratify patients into prognostic subgroups. High TRIM47 expression frequently coincides with more aggressive molecular subtypes, increased immune cell infiltration and differential responses to immune checkpoint inhibitors, transarterial chemoembolization or multi‐kinase inhibitors such as sorafenib, implying that TRIM47 may serve as a composite marker of both tumor‐intrinsic biology and microenvironmental state [34]. In idiopathic pulmonary fibrosis, integrated analyses of bronchoalveolar lavage transcriptomes and curated E3 ligase gene sets have yielded a five‐gene prognostic model in which TRIM47 is a key component; high‐risk patients in this model show enrichment of extracellular matrix organization and TGF‐β–driven fibrotic pathways, consistent with experimental data on TRIM47‐mediated PPM1A degradation and SMAD activation [35]. In multiple myeloma, ubiquitin–proteasome signatures that include TRIM47 correlate with survival and immune status, suggesting that TRIM47 may participate in proteostasis disturbances and immune dysregulation in hematologic malignancy [36, 37]. Similarly, in uveal melanoma, a four‐gene signature encompassing NAT10, TRIM47, ISG20, CEBPB and ATG9A links TRIM47 to networks involving RNA modification, autophagy and innate immunity, again placing it at the intersection of tumor cell–intrinsic and immune‐modulatory processes [38].

Evidence from post‐translational modification (PTM)–focused multi‐omics extends TRIM47's reach into neurodegenerative disease. A recent systematic analysis of PTM‐related genes across multiple brain and blood cohorts proposed a PTM score that robustly discriminates Alzheimer's disease from controls and tracks with canonical biomarkers. Within this framework, TRIM47 is identified as a putative therapeutic target, with expression levels associated with cerebrospinal fluid amyloid‐β and phosphorylated tau, as well as hippocampal volume [39, 40]. While these data do not yet establish causality, they support the concept that TRIM47‐mediated ubiquitination and related PTMs may modulate protein aggregation, clearance or neuronal vulnerability in Alzheimer's disease, thereby extending the TRIM47 disease spectrum into chronic neurodegeneration.

Whole‐genome and transcriptome sequencing studies have also revealed structural variation implicating TRIM47 in DNA repair–related oncogenic processes. In pancreatic acinar cell carcinoma, comprehensive genomic profiling has identified a BRCA1::TRIM47 fusion in the context of germline BRCA1 or FANCL mutations, together with a mutational landscape consistent with homologous recombination deficiency. This fusion is hypothesized to further compromise BRCA1 function and augment genomic instability, potentially explaining marked sensitivity to PARP inhibition in the affected patient. Coupled with proteomic evidence that TRIM47 can modulate PARP1 activity and BRCA1‐related pathways in other cancers, these observations point to a role for TRIM47 not only as an E3 ligase acting on DNA repair factors, but also as a structural fusion partner that reshapes repair networks and therapeutic vulnerabilities [31, 32, 41].

Despite the breadth of these observations, important limitations and knowledge gaps remain. First, many genetic and transcriptomic associations are correlative and do not disentangle TRIM47 from neighboring genes at the 17q25 locus or from co‐regulated ubiquitin pathway components within multigene signatures. Second, most multi‐omics studies treat TRIM47 as one feature among many, with limited functional validation to confirm that it is a true driver rather than a surrogate marker of broader pathway activation. Third, cross‐cohort heterogeneity in patient populations, sample types, and analytical methods complicates direct comparison of TRIM47‐related signatures across diseases. Finally, there is often a disconnect between the tissues sampled in omics studies (e.g., bronchoalveolar lavage or peripheral blood) and the primary sites of TRIM47 action inferred from experimental models.

2.5. Established Knowledge and Unresolved Questions

Taken together, current data delineate a growing list of TRIM47 substrates that cluster into several functional modules. One module encompasses deubiquitinases and phosphatases (CYLD, SIRT1, PPM1A) that normally restrain inflammatory and fibrotic signaling; their TRIM47‐mediated degradation shifts cells toward sustained activation of NF‐κB, MAPK, and TGF‐β cascades. A second module involves metabolic enzymes (FBP1, CDO1) whose loss promotes Warburg metabolism, antioxidant defense, and ferroptosis resistance in cancer. A third module consists of classical tumor suppressors and apoptosis regulators (p53, Smad4, XAF1) that govern cell‐cycle arrest, differentiation, and cell death, and whose inactivation by TRIM47 favors tumorigenesis and progression. A fourth module includes signaling adaptors and scaffold proteins (NEMO, IκBα, NF90, PPM1A) that integrate innate immunity, stress, and inflammatory responses. Finally, DNA repair factors such as BRCA1 and PARP1 are emerging as TRIM47‐linked targets in breast, gallbladder, and pancreatic acinar carcinomas, with implications for homologous recombination deficiency and sensitivity to PARP inhibition [33, 35]. Despite substantial progress, TRIM47 biology remains poorly defined: substrates are identified in isolated models with limited validation, ubiquitination sites and chain types are unmapped, structural and interactome data are lacking, and tissue‐ and context‐specific functions are unclear, hindering interpretation and therapeutic exploitation.

Nevertheless, the convergence of evidence from GWAS loci, bulk and single‐cell transcriptomics, proteomics, PTM‐wide analyses and structural variant profiling consistently draws TRIM47 into the orbit of multiple disease domains, including cerebral small vessel disease, pulmonary fibrosis, liver cancer, plasma cell dyscrasias, ocular melanoma, Alzheimer's disease and rare pancreatic malignancies. This multi‐layered signal strongly supports the notion that TRIM47 is not a contextually isolated factor but rather a recurrent node in human pathophysiology. Integrating these genetic and multi‐omics data with mechanistic studies is therefore essential for constructing a coherent model of how TRIM47 contributes to inflammation, organ damage and tumor biology, and for assessing whether disease‐associated TRIM47 signatures can be translated into clinically meaningful biomarkers or therapeutic entry points.

3. Shared Non‐Neoplastic Programs of TRIM47: Inflammatory Amplification, Tissue Injury, and Fibrotic Remodeling

3.1. Inflammatory Amplification and Innate Immune Dysregulation

Beyond cancer, one of the earliest and most recurrent functions attributed to TRIM47 is the amplification of inflammatory signaling in non‐neoplastic settings. Across diverse cellular and tissue contexts, TRIM47 repeatedly converges on NF‐κB‐centered pathways, thereby strengthening cytokine production, inflammasome priming, and tissue‐damaging immune activation. Rather than acting as a generic stress marker, TRIM47 appears to function as an active signaling amplifier whose effects are shaped by substrate choice and ubiquitin‐chain topology.

This inflammatory logic is particularly evident in barrier and innate immune‐associated tissues. Airway epithelial models provide further support for TRIM47 as an amplifier of barrier inflammation and inflammatory cell death. In human bronchial epithelial cell lines (BEAS‐2B and 16HBE) stimulated with house dust mite, TRIM47 expression is robustly upregulated and functions as an upstream activator of the NF‐κB/NLRP3 axis. Specifically, TRIM47 binds to the NF‐κB essential modulator NEMO and catalyzes K63‐linked ubiquitination, enhancing IKK activation, IκBα phosphorylation, and p65 nuclear translocation. This NF‐κB activation, in turn, drives transcription of NLRP3 and pro–IL‐1β, fosters assembly of the NLRP3 inflammasome, and promotes caspase‐1–dependent cleavage of gasdermin D. The resulting gasdermin D N‐terminal fragment executes pyroptotic cell death, accompanied by the release of IL‐1β and IL‐18, as well as upstream epithelial “alarmins” such as IL‐25, IL‐33, and thymic stromal lymphopoietin. Collectively, these events position TRIM47 as a critical amplifier of allergen‐induced epithelial pyroptosis and cytokine release, processes that are central to the pathogenesis of asthma and other type 2 inflammatory airway diseases [29].

A complementary aspect of TRIM47 biology is its ability to weaken stress‐limiting and antiviral restraints. In antiviral innate immunity, TRIM47 has been characterized as a negative regulator of RNA virus responses via the Tim‐3–TRIM47–NF90 axis. Upon engagement of the immune checkpoint receptor Tim‐3, TRIM47 is recruited to stress granule–associated complexes and catalyzes K48‐linked ubiquitination of NF90 at Lys297, targeting NF90 for proteasomal degradation. NF90 is a double‐stranded RNA‐binding protein that promotes stress granule assembly and supports antiviral gene expression; its depletion by TRIM47 disrupts stress granules and attenuates type I interferon and other antiviral programs in response to vesicular stomatitis virus and related RNA viruses. This mechanism suggests that TRIM47 contributes to the fine‐tuning of innate antiviral responses, restraining excessive activation but also potentially facilitating viral persistence. The fact that Tim‐3 is widely expressed on exhausted T cells and various tumor‐infiltrating immune populations raises the possibility that TRIM47‐mediated NF90 degradation also supports tumor immune evasion by dampening local antiviral and danger‐sensing pathways within the tumor microenvironment, although this link remains largely inferential [30].

This general inflammatory logic is also recapitulated in the central nervous system. In ischemic or anesthetic brain injury models, TRIM47 upregulation is associated with enhanced NF‐κB activation, cytokine induction, oxidative stress, and neuronal injury. Although the precise substrates are less completely defined than in epithelial or fibrotic models, the same overarching pattern remains evident: TRIM47 operates upstream of inflammatory amplification, thereby linking cellular stress to maladaptive tissue responses [42, 43].

3.2. Brake Removal in Tissue Injury and Fibrotic Remodeling

Across liver, kidney, and lung injury, TRIM47 repeatedly promotes disease not by creating entirely distinct tissue‐specific pathways, but by removing endogenous inhibitory brakes on inflammatory and profibrotic signaling. This “brake removal” logic represents one of the most coherent non‐neoplastic functions of TRIM47 and provides a unifying framework for interpreting its roles across organ injury models.

In the liver, TRIM47 has been linked to steatohepatitis and fibrotic progression through degradation of the deubiquitinase CYLD. Because CYLD normally constrains TAK1‐dependent signaling, its TRIM47‐mediated loss leads to sustained activation of JNK and p38, thereby coupling metabolic stress to persistent inflammatory and fibrogenic output. In this setting, TRIM47 functions upstream of a signaling cascade that transforms transient stress into chronic inflammatory remodeling [21, 44].

A similar pattern is observed in immune‐mediated kidney injury, where TRIM47 promotes degradation of SIRT1 in glomerular endothelial cells. Since SIRT1 normally restrains proinflammatory HMGB1 activity, its loss facilitates HMGB1 acetylation and release, amplifies endothelial–podocyte inflammatory crosstalk, and contributes to podocyte injury and renal dysfunction. Thus, in the kidney, TRIM47 again acts by dismantling a protective checkpoint rather than by initiating an entirely novel signaling pathway [15, 45].

In the lung, TRIM47 has been implicated in bleomycin‐induced pulmonary fibrosis through degradation of PPM1A, a phosphatase that normally terminates TGF‐β/SMAD and NF‐κB‐related signaling. Loss of PPM1A releases these pathways from negative control, resulting in enhanced fibroblast activation, epithelial injury, inflammasome signaling, and extracellular matrix remodeling. Importantly, pharmacologic activation of PPM1A can partially counter this pathogenic program, highlighting that TRIM47‐driven brake removal may be therapeutically reversible in selected contexts [35].

Although the immediate substrate differs across liver, kidney, and lung, the signaling logic is highly conserved. In each case, TRIM47 targets a molecule that ordinarily restrains inflammation, stress signaling, or fibrotic remodeling; once that brake is removed, the injured tissue shifts toward persistent inflammatory activation, maladaptive repair, and progressive fibrosis. This recurrent pattern argues that tissue diversity at the phenotypic level converges on a shared TRIM47‐dependent mechanism of pathological signal reinforcement.

3.3. The Inflammation–Cell Death–Fibrosis Continuum

When considered across tissues, TRIM47‐associated non‐neoplastic pathology is best understood not as a collection of isolated disease‐specific observations, but as a continuum linking inflammatory amplification, stress‐associated cell injury or death, and subsequent fibrotic remodeling. This framework helps explain why TRIM47 repeatedly emerges in liver, kidney, lung, and brain injury models despite apparent differences in tissue architecture and proximal triggers.

The first stage of this continuum involves amplification of inflammatory signaling. Through actions on NEMO, CYLD, SIRT1, PPM1A, NF90, and related regulators, TRIM47 enhances NF‐κB‐centered inflammatory pathways, stress kinase activation, HMGB1 signaling, and inflammasome priming. These effects create a cellular environment in which damage signals are not efficiently contained, but instead propagate and intensify [15, 29].

The second stage involves cell injury and stress‐associated loss of tissue homeostasis. Depending on context, this may manifest as epithelial pyroptosis, neuronal injury, endothelial dysfunction, podocyte damage, or broader parenchymal stress responses. Although the dominant cell‐death modality may differ among tissues, the broader principle remains the same: TRIM47 shifts stressed cells away from adaptive restraint and toward injury‐amplifying programs [9].

The third stage is maladaptive remodeling, most clearly represented by fibrosis. Sustained activation of TGF‐β/SMAD, NF‐κB, MAPK, and related pathways promotes extracellular matrix deposition, fibroblast activation, and failure of injury resolution. In this way, TRIM47 links early inflammatory disequilibrium to later structural remodeling and chronic organ dysfunction. Importantly, this framework also provides a mechanistic bridge to later sections of the review: the same inflammatory and stress‐rewiring logic that drives non‐neoplastic injury may also shape tumor‐promoting microenvironments and influence therapeutic response [12].

Overall, the inflammation–cell death–fibrosis continuum offers a more coherent interpretation of TRIM47 biology than a simple organ‐by‐organ description. It emphasizes that different non‐neoplastic disease phenotypes may arise from repeated engagement of a limited number of shared signaling modules, thereby positioning TRIM47 as a recurrent amplifier of maladaptive tissue responses rather than a series of unrelated disease‐specific factors.

3.4. Contextual Extensions in the Central Nervous System and Other Chronic Inflammatory Settings

Although the strongest mechanistic evidence currently comes from liver, kidney, and lung models, the same TRIM47‐dependent logic may extend to additional chronic inflammatory settings. In the central nervous system, ischemia–reperfusion injury and anesthetic neurotoxicity both show associations between TRIM47 upregulation, NF‐κB activation, cytokine induction, and neuronal damage, suggesting that inflammatory amplification by TRIM47 is not restricted to classical peripheral organs [9, 43].

A similar conceptual extension may apply to chronic inflammatory stromal disorders. In rheumatoid arthritis fibroblast‐like synoviocytes, preliminary evidence suggests that TRIM47‐related NF‐κB circuits may contribute to hyperproliferative, tumor‐like stromal expansion. Although current evidence in this area remains less mature than in liver, kidney, or lung injury, such observations broaden the relevance of TRIM47 from acute tissue injury to chronic inflammatory remodeling states [46].

These contextual extensions remain mechanistically less resolved, but they support a broader working model in which TRIM47 functions as a context‐dependent amplifier of inflammatory disequilibrium, tissue stress, and pathological remodeling across non‐neoplastic disease settings (Table 2).

TABLE 2.

TRIM47 in non‐neoplastic diseases and organ injury.

Disease	Human sample/dataset	TRIM47 status vs. control	Reported association	Key mechanistic axis (as reported)	References
PF	PF transcriptomic cohorts; mouse bleomycin models	Upregulated in fibrotic lung; enriched in high‐risk PF signature	High TRIM47 (with low PPM1A) associated with worse survival and more severe fibrosis	PPM1A K48‐ubiquitination → TGF‐β/SMAD3 and NF‐κB/NLRP3 activation; otilonium bromide activates PPM1A and counteracts TRIM47	[14]
	Public IPF transcriptomic cohorts	TRIM47 one of five E3 genes upregulated in high‐risk group	High‐risk score including TRIM47 predicts poorer overall survival	Signature implicates TRIM47 in pro‐fibrotic TGF‐β/ECM networks	[35]
NASH	Diet‐induced NASH models; human and primate liver samples	TRIM47 upregulated with steatohepatitis severity	Higher TRIM47 parallels more severe inflammation and fibrosis	CYLD K48‐ubiquitination → sustained TAK1–JNK/p38 signaling → hepatic inflammation and fibrogenesis	[20]
Immune kidney injury	Mouse models of TCE‐induced immune kidney injury	TRIM47 upregulated	Higher TRIM47 associated with worse renal dysfunction and glomerular injury	SIRT1 K48‐ubiquitination → HMGB1 acetylation and release → podocyte inflammation and apoptosis	[15]
Cerebral small vessel disease	Gene‐mapping study of extremes of WMH burden	Risk alleles near TRIM47–TRIM65 locus associated with higher WMH volume	Genetic variants linked to increased WMH load and susceptibility to cerebral small vessel disease	TRIM47 may influence brain endothelial homeostasis and autophagy‐related barrier responses	[5, 9]
AD	Multi‐omics PTM‐score analysis	Higher TRIM47 expression associated with higher PTM‐score	TRIM47 levels correlate with CSF Aβ, phosphorylated tau and hippocampal atrophy indices	PTM‐based model highlights TRIM47 as potential modulator/biomarker	[40]

Abbreviations: Aβ, amyloid beta; AD, Alzheimer's disease; CSF, cerebrospinal fluid; NASH, non‐alcoholic steatohepatitis; IPF, idiopathic pulmonary fibrosis; PF, pulmonary fibrosis; PTM, post‐translational modifications, TCE, trichloroethylene; WMH, white matter hyperintensities.

4. Oncogenic Pathways and Tumor Progression

Over the past decade, TRIM47 has emerged not simply as a recurrently overexpressed factor across multiple tumor types, but as a context‐dependent E3 ligase that repeatedly rewires a limited number of core programs supporting malignant fitness. Across cancers, these programs include cell‐cycle progression and apoptosis escape, metabolic adaptation and ferroptosis resistance, DNA damage remodeling, invasive plasticity, and microenvironmental or immune modulation. This mechanism‐centered view provides a more coherent framework than a tumor‐by‐tumor description for understanding how TRIM47 contributes to cancer progression. Consistent with this view, TRIM47 is recurrently upregulated in non–small‐cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, colorectal and gastric cancers, gallbladder carcinoma, ovarian and breast cancers, prostate cancer, glioma, and head and neck squamous cell carcinoma, where higher expression often correlates with advanced stage and worse outcome. For ease of reference, the tumor‐specific evidence supporting TRIM47‐driven progression is organized in Figure 1 and Table 1.

FIGURE 1.

Spectrum of TRIM47 in human tumors. Schematic overview of malignancies in which TRIM47 dysregulation has been reported. The circular layout highlights major tumor entities linked to TRIM47 overexpression and/or functional involvement, including gastric cancer, renal cell carcinoma, prostate cancer, gallbladder cancer and pancreatic adenocarcinoma, multiple myeloma, uveal melanoma, breast cancer, colorectal cancer, hepatocellular carcinoma and non–small‐cell lung cancer. Across these settings, published evidence suggests that elevated TRIM47 commonly correlates with aggressive clinicopathologic features and adverse outcomes, and mechanistic studies implicate TRIM47 in tumor‐promoting programs such as proliferation and survival, metabolic reprogramming and ferroptosis resistance, DNA damage response modulation, and invasion/EMT. This figure provides a visual synopsis of the tumor disease landscape discussed in the main text.

4.1. Cell‐Cycle Control and Apoptosis Escape

A first major oncogenic module controlled by TRIM47 involves the neutralization of anti‐proliferative and pro‐apoptotic checkpoints. In renal cell carcinoma, TRIM47 directly ubiquitinates and destabilizes p53, weakening a central barrier to malignant proliferation and survival [22]. In prostate cancer, TRIM47 promotes tumor growth via the MDM2–p53 axis: silencing TRIM47 reduces MDM2 levels, stabilizes p53, and induces cell‐cycle arrest and apoptosis, highlighting both direct and indirect avenues by which TRIM47 can inactivate p53 signaling [26]. In head and neck squamous cell carcinoma, TRIM47 targets XAF1, a pro‐apoptotic antagonist of XIAP, for ubiquitin‐dependent degradation, thereby counteracting apoptosis and favoring tumor progression [24]. Thus, TRIM47 promotes malignant fitness not through a single cancer‐specific effector, but by repeatedly dismantling molecular barriers to proliferation and survival.

4.2. Metabolic Reprogramming and Ferroptosis Resistance

A second recurrent oncogenic module involves metabolic rewiring coupled to protection from ferroptotic cell death. In pancreatic cancer, TRIM47 mediates K48‐linked ubiquitination of the gluconeogenic enzyme FBP1, lowering its abundance and thereby promoting aerobic glycolysis (the Warburg effect), which supports rapid cell proliferation and in vivo tumorigenesis [17]. In prostate cancer, TRIM47 regulates both FBP1 and FOXO1, orchestrating a broader metabolic shift that enhances glycolytic flux while suppressing ferroptosis, a form of iron‐dependent lipid peroxidation–driven cell death [26]. In hepatocellular carcinoma, TRIM47 targets the cysteine dioxygenase CDO1 for degradation, preserving intracellular cysteine and glutathione levels, inhibiting ferroptosis and facilitating tumor progression [21]. Across these models, a coherent pattern emerges in which TRIM47‐driven degradation of metabolic enzymes reprograms energy metabolism and redox homeostasis, simultaneously fueling growth and providing escape from ferroptotic cell death. This positions TRIM47 as a key regulator of the metabolic–cell death interface in cancer.

4.3. DNA Damage Responses and PARP–BRCA Network

A third functional axis links TRIM47 to DNA damage responses and the PARP–BRCA repair network. In triple‐negative breast cancer, TRIM47 has been reported to ubiquitinate BRCA1, impairing homologous recombination repair and paradoxically enhancing sensitivity to PARP inhibition; in this setting, high TRIM47 expression may identify tumors more likely to respond to PARP inhibitors, despite its underlying oncogenicity [31]. In gallbladder cancer, TRIM47 promotes K63‐linked ubiquitination and activation of PARP1, driving tumor growth and survival while potentially creating a therapeutic liability whereby PARP inhibition becomes particularly effective [32]. Whole‐genome and transcriptome sequencing in pancreatic acinar cell carcinoma has uncovered a BRCA1::TRIM47 fusion occurring in the context of germline BRCA1 or FANCL mutations and a classic homologous recombination–deficient signature. This fusion likely exacerbates BRCA1 dysfunction and contributes to marked clinical responsiveness to PARP inhibitors [41]. Together, these observations suggest that TRIM47 can simultaneously promote tumor evolution and reshape the DNA‐repair landscape in ways that may increase dependence on PARP‐centered pathways (Table 3).

TABLE 3.

TRIM47 in human tumors.

Tumor type	Human sample/dataset	TRIM47 status vs. control	Clinical/phenotypic association	Key mechanistic axis	References
Gastric cancer	Tumor vs. adjacent tissue (IHC, mRNA); cell lines	Upregulated	Larger tumors, advanced TNM stage, poorer overall survival	CYLD K48‐ubiquitination → NF‐κB activation → proliferation, migration, invasion	[25]
NSCLC	NSCLC tissue microarrays (IHC); in vitro assays	Upregulated	Poor differentiation, nodal metastasis, shorter survival	Oncogenic signaling activation (e.g., PI3K/AKT) promoting growth and invasion	[16]
RCC	RCC specimens (IHC); cell lines and xenografts	Upregulated	Aggressive features, worse outcome	E3 ligase for p53 → p53 degradation → increased proliferation and invasion	[22]
HCC	HCC tissues (IHC); public cohorts; cell lines and xenografts	Upregulated	Poor survival, altered immune infiltration	CDO1 K48‐ubiquitination → ferroptosis suppression; contribution to TRIM/UPS risk models	[21]
Gallbladder cancer	Gallbladder carcinoma tissue (IHC, mRNA); cell lines	Upregulated	Advanced stage, nodal metastasis, poor survival	K63‐linked ubiquitination of PARP1 → enhanced DNA damage signaling and tumor progression	[32]
Colorectal cancer	CRC tissues and cell lines	Upregulated	Advanced stage, poorer prognosis	Smad4 ubiquitination and degradation → enhanced proliferation, migration and invasion	[23]
Pancreatic ductal adenocarcinoma	Pancreatic cancer tissues; cell lines; xenografts	Upregulated	Promote tumor growth in vivo	FBP1 ubiquitination → Warburg effect enhancement → tumor progression	[17]
Pancreatic acinar cell carcinoma	Whole‐genome/transcriptome analysis of PARPi‐treated PACC	BRCA1::TRIM47 fusion present in PARPi‐sensitive tumor	Fusion associated with homologous recombination deficiency and marked PARP inhibitor sensitivity	BRCA1–TRIM47 structural fusion compromising BRCA1 and creating PARPi dependency	[41]
Prostate cancer	Prostate cancer specimens; cell lines; xenografts	Upregulated	Tumor growth; clinical prognostic data limited	Regulation of FBP1 and FOXO1 → Warburg effect enhancement and ferroptosis suppression	[26]
Breast cancer	Breast cancer tissues; cell lines	Upregulated	Increased proliferation, tumor growth in models	PI3K/Akt activation; TRIM47 knockdown suppresses growth	[47]
	ER+ breast cancer cell lines; endocrine‐treated cohorts	Higher in endocrine‐resistant cells/tumors	Poor response to endocrine therapy	Stabilization of PKCε/PKD3 → sustained NF‐κB signaling → endocrine resistance	[31]
Ovarian cancer	Ovarian cancer tissues; paclitaxel‐resistant models	Upregulated	Paclitaxel resistance	METTL3–m6A stabilizes TRIM47 mRNA; TRIM47 degrades PPM1A → TGF‐β/SMAD activation	[19]
Glioma	Glioma tissues; public datasets; cell lines; HUVEC assays	Upregulated	Poorer survival and increased angiogenesis	FOXO1 degradation promoting proliferation; glioma cell–driven endothelial tube formation	[28]
Head and neck squamous cell carcinoma	Hypopharyngeal and laryngeal cancer specimens; NSCC cell lines	Overexpressed	Advanced stage and worse prognosis	Vimentin K63‐ubiquitination and/or XAF1 degradation → invasion, metastasis and apoptosis resistance	[24]
Multiple myeloma	Gene‐expression cohorts for UPS‐based risk score	Included in high‐risk UPS signature	High UPS score including TRIM47 predicts shorter overall survival	Part of UPS dysregulation signature; individual functional role not tested in MM	[37]
Uveal melanoma	TCGA‐UVM and transcriptome/scRNA‐seq datasets; NAT10‐related signature	Component of high‐risk NAT10‐related gene signature	High‐risk group including TRIM47 shows poorer survival and distinct immune infiltration	Links TRIM47 to RNA modification, autophagy and immune regulation in UVM	[38]

Abbreviations: HCC, hepatocellular carcinoma; NSCLC, non–small‐cell lung carcinoma; RCC, renal cell carcinoma.

4.4. Invasion, EMT and Angiogenesis

TRIM47 also contributes to invasion, migration, and angiogenesis through EMT and TGF‐β–related pathways. In breast cancer, particularly hormone receptor–positive disease, TRIM47 has been linked to activation of PI3K/Akt signaling and enhancement of epithelial–mesenchymal transition (EMT), contributing to increased proliferation, survival, and metastatic dissemination [47]. In gastric cancer and NSCLC, elevated TRIM47 expression associates with EMT marker shifts, NF‐κB activation, and increased migratory and invasive capacity in vitro and in vivo [16, 48, 49]. In gliomas, TRIM47 suppresses Smad4, weakening TGF‐β tumor‐suppressive signals while enhancing endothelial tube formation and tumor angiogenesis in co‐culture and xenograft models [28]. In colorectal cancer, TRIM47 similarly promotes invasion and metastasis at least in part via degradation of Smad4 and disruption of TGF‐β–mediated growth restraint [23]. Across these contexts, TRIM47 appears to facilitate a mesenchymal, pro‐invasive phenotype and to support vascular remodeling, thereby linking intracellular signaling changes to tissue‐level patterns of dissemination and neovascularization.

4.5. Tumor Microenvironment and Immune Modulation

Finally, growing evidence implicates TRIM47 in shaping the tumor microenvironment and anti‐tumor immunity. In hepatocellular carcinoma, TRIM family and ubiquitin–proteasome signatures that include TRIM47 correlate with immune cell infiltration patterns and clinical responses to immune checkpoint blockade, transarterial chemoembolization and tyrosine kinase inhibitors [34]. In uveal melanoma, a composite risk score incorporating NAT10, TRIM47, ISG20, CEBPB and ATG9A associates with distinct immune infiltration profiles and immune checkpoint expression, indicating that TRIM47 participates in networks linking RNA modification, autophagy and innate immunity to TME composition [38]. Beyond classical neoplasia, TRIM47‐driven NF‐κB activation in rheumatoid arthritis fibroblast‐like synoviocytes fosters hyperproliferation and invasive pannus formation, providing an example of “tumor‐like” stromal expansion driven by similar E3 ligase circuits [46, 50]. These data suggest that TRIM47 may influence not only tumor cell–intrinsic programs but also the immune and inflammatory architecture of the tumor microenvironment.

Despite these advances, several limitations temper current understanding. Most tumor studies are based on small cohorts or single‐centre datasets and rely heavily on correlative expression analyses, with limited pan‐cancer integration. Functional work often uses overexpression or transient knockdown without orthogonal validation in genetic knockout models or patient‐derived organoids. The context dependence of TRIM47's effects—particularly its dual role in promoting malignancy while sensitizing to PARP inhibition—remains incompletely defined across histologies and genomic backgrounds, and systematic mapping of TRIM47 substrates within specific tumor types and microenvironmental compartments, as well as potential redundancy or synergy with other TRIM family members, is lacking. Nonetheless, cumulative data firmly establish TRIM47 as a multimodal oncogenic regulator that coordinates cell‐cycle control, apoptosis, metabolism, ferroptosis, DNA repair, invasion and immune modulation through its E3 ligase activity.

5. TRIM47 As a Double‐Edged Regulator of Therapy Response

Therapeutic resistance is a major obstacle in the management of both solid tumors and chronic inflammatory or fibrotic diseases. Across these contexts, TRIM47 is increasingly recognized not only as a driver of disease biology but also as a modulator of treatment response—a “treatment response regulator” whose activity can either undermine standard therapies or create new vulnerabilities that can be therapeutically exploited. Rather than functioning uniformly as a resistance factor, TRIM47 appears to reshape therapeutic response in a context‐dependent manner, either by reinforcing pro‐survival signaling or by creating pathway dependencies that can be therapeutically exploited.

5.1. Platinum and Taxane Resistance

For cytotoxic therapy, the strongest current evidence positions TRIM47 as a facilitator of chemoresistance by dampening cell death signaling and stabilizing pro‐survival transcriptional programs. In cisplatin‐treated ovarian cancer models, high TRIM47 expression confers resistance by attenuating endoplasmic reticulum (ER) stress–induced apoptosis. Specifically, TRIM47 upregulation blunts activation of the pro‐apoptotic transcription factor CHOP and downstream ER stress effectors, thereby allowing tumor cells to survive DNA damage that would otherwise trigger cell death. Genetic silencing of TRIM47 restores ER stress signaling, enhances apoptosis and resensitizes cells to cisplatin, implicating TRIM47 as an upstream brake on ER stress–mediated chemosensitivity. In the taxane setting, paclitaxel‐resistant ovarian cancer cells exhibit METTL3‐dependent m6A methylation and stabilization of TRIM47 mRNA. Elevated TRIM47 then ubiquitinates and destabilizes PPM1A, relieving inhibition of TGF‐β/SMAD signaling and promoting a pro‐survival, mesenchymal phenotype that supports paclitaxel resistance. Knockdown of either TRIM47 or METTL3 reduces TGF‐β/SMAD activation and restores paclitaxel sensitivity, linking epitranscriptomic regulation of TRIM47 to chemotherapy response. These convergent findings position TRIM47 as a central node in platinum and taxane resistance through coordinated control of ER stress and TGF‐β signaling [19, 51].

5.2. DNA‐Repair Remodeling and PARP‐Centered Vulnerability

In contrast to its resistance‐promoting role for cytotoxics, TRIM47 can paradoxically increase dependence on the DNA damage response machinery and thereby enhance sensitivity to PARP inhibition. In triple‐negative breast cancer, TRIM47 has been reported to ubiquitinate BRCA1, functionally compromising homologous recombination repair and augmenting reliance on PARP‐mediated single‐strand break repair. As a result, tumors with high TRIM47 and pre‐existing defects in BRCA1 function may be particularly vulnerable to PARP inhibitors, even as TRIM47 promotes tumorigenesis. In gallbladder cancer, TRIM47 enhances K63‐linked ubiquitination and activation of PARP1, driving tumor progression but simultaneously creating a state of heightened PARP1 dependence that could be therapeutically targeted. Whole‐genome and transcriptome analyses in pancreatic acinar cell carcinoma extend this concept to the structural level: a BRCA1::TRIM47 fusion in the background of germline BRCA1 or FANCL mutations and homologous recombination deficiency is associated with profound clinical responsiveness to PARP inhibition. Together, these studies support the idea that high TRIM47 expression in a homologous recombination–deficient background may serve as a composite biomarker for PARP inhibitor benefit, while also underscoring the dualistic nature of TRIM47 as both an oncogenic driver and a determinant of targeted therapy susceptibility [31, 32, 41].

5.3. Endocrine Resistance

TRIM47 additionally contributes to resistance against endocrine and other targeted therapies. In estrogen receptor–positive breast cancer, TRIM47 promotes endocrine resistance by stabilizing PKCε and PKD3, kinases that feed into NF‐κB activation and pro‐survival transcriptional programs. Sustained NF‐κB signaling undermines the cytostatic and pro‐apoptotic effects of endocrine agents, leading to persistent proliferation despite estrogen deprivation or receptor blockade. Experimental depletion of TRIM47 destabilizes PKCε/PKD3, diminishes NF‐κB activity and partially restores sensitivity to endocrine therapy, implicating TRIM47 as an upstream effector of ligand‐independent survival signaling in hormone‐dependent breast cancer. Similar TRIM47–NF‐κB circuits are likely relevant for resistance to other targeted agents in tumors where inflammatory signaling underwrites escape from oncogene‐directed therapies, although direct evidence remains limited [6, 52].

5.4. Antifibrotic and Nutritional Interventions

Beyond oncology, several studies highlight how modulation of TRIM47 or its substrates can be leveraged by repurposed drugs or dietary interventions to improve responses in fibrotic and inflammatory disease. In bleomycin‐induced pulmonary fibrosis, the PPM1A activator otilonium bromide counteracts TRIM47‐mediated PPM1A degradation, thereby restraining TGF‐β/SMAD3 and NF‐κB/NLRP3 signaling and attenuating fibrosis. Genetic knockdown of PPM1A markedly diminishes the antifibrotic effect of otilonium, confirming that pharmacologic activation of a TRIM47 substrate can therapeutically override TRIM47‐driven disease mechanisms. In microglial oxygen–glucose deprivation/reoxygenation models, the flavonoid acacetin modulates Trim47 alternative splicing and broader ubiquitin pathway gene expression, reducing inflammatory gene induction, oxidative stress, and cell death; although TRIM47 is not the sole target, these data suggest that fine‐tuning TRIM47 isoform balance may contribute to the neuroprotective effects of acacetin. In gastric cancer, methionine restriction emerges as a metabolic intervention that suppresses TRIM47 expression, stabilizes IκBα, and limits NF‐κB–dependent EMT and metastasis. Overexpression of TRIM47 partially reverses the anti‐metastatic benefit of methionine restriction, implicating TRIM47 downregulation as a mechanistic contributor to diet‐mediated tumor control [14, 49, 53]. These observations broaden the therapeutic relevance of TRIM47 from a marker of drug resistance to a manipulable node within pathway‐ and metabolism‐directed intervention strategies.

5.5. Context‐Dependent Therapy Response

Taken together, current evidence supports a unifying interpretation: TRIM47 is best understood as a double‐edged regulator of treatment response. In several solid tumors, high TRIM47 expression underlies resistance to platinum, taxane, and endocrine therapies by dampening ER stress, activating TGF‐β and NF‐κB pathways, and stabilizing pro‐survival signaling complexes. Conversely, in DNA repair–defective settings, TRIM47‐mediated perturbation of BRCA1 and PARP1 can accentuate homologous recombination deficiency and render tumors more susceptible to PARP inhibition. In fibrotic and inflammatory diseases, pharmacologic or nutritional interventions that either oppose TRIM47's effects on substrates such as PPM1A or reduce its expression can ameliorate disease and potentially enhance the efficacy of standard treatments.

Despite these promising insights, several limitations constrain translation. Most data derive from preclinical models with limited clinical validation, and the extent to which TRIM47 expression or activity predicts treatment response in real‐world cohorts remains largely unknown. Context specificity is incompletely defined; the same TRIM47‐dependent pathway may have divergent effects depending on tumor genotype, microenvironment, or treatment history. Direct pharmacologic inhibitors of TRIM47 are not yet available, and strategies that modulate upstream regulators such as METTL3 or downstream substrates may have broad off‐target consequences. These gaps underscore the need for systematic, therapy‐focused studies that integrate TRIM47 expression, functional assays, and clinical outcomes across modalities. Nevertheless, the current body of work firmly establishes TRIM47 as a double‐edged regulator of therapy response. Recognizing when it primarily acts as a resistance factor versus when it creates exploitable dependencies will be critical for designing rational combinations, selecting patients for PARP‐ or pathway‐targeted therapies, and determining whether direct or indirect targeting of TRIM47 can be safely and effectively incorporated into precision treatment of cancer and fibrotic disease.

6. Translational Outlook and Unresolved Questions

6.1. What TRIM47 Can Currently Offer as a Biomarker

The recurrent dysregulation of TRIM47 across inflammatory, fibrotic, and malignant diseases naturally raises the question of whether it may have translational value as a biomarker. At present, the strongest evidence supports TRIM47 as an exploratory marker of biological aggressiveness rather than as a clinically validated standalone assay. In multiple solid tumors, including gastric cancer, non–small‐cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, gallbladder carcinoma, and prostate cancer, TRIM47 overexpression at the mRNA or protein level is associated with advanced stage, metastatic behavior, and worse survival. In this setting, TRIM47 appears to capture aggressive tumor biology and may provide information complementary to conventional clinicopathologic variables. Beyond single‐gene measurements, TRIM47 is also incorporated into multigene signatures in idiopathic pulmonary fibrosis, multiple myeloma, uveal melanoma, and Alzheimer's disease, where it contributes to risk stratification and disease subtyping. Taken together, these observations suggest that TRIM47 recurrently marks pathogenic signaling states across both malignant and non‐malignant disease contexts [35].

A second, potentially more clinically consequential dimension is the predictive value of TRIM47 in treatment response. Current data suggest that TRIM47 may help define contexts of resistance or pathway dependency rather than simply serving as a general prognostic factor. In ovarian cancer, elevated TRIM47 is linked to reduced sensitivity to cisplatin and paclitaxel, consistent with its ability to suppress stress‐associated apoptosis and reinforce TGF‐β–linked survival signaling. In contrast, in selected DNA repair‐defective contexts, TRIM47‐associated perturbation of BRCA1/PARP1 circuitry may help define PARP‐vulnerable states. Outside oncology, TRIM47‐related signaling also appears relevant to antifibrotic and metabolic intervention, as illustrated by PPM1A‐centered modulation in pulmonary fibrosis and TRIM47 downregulation under methionine restriction in gastric cancer. However, these predictive associations remain preliminary and should currently be interpreted as hypothesis‐generating rather than practice‐changing. Overall, TRIM47 may offer value across the diagnostic–prognostic–predictive spectrum, but this value is presently strongest at the level of recurrent biological signal rather than validated clinical utility [49, 51].

6.2. Why Current Evidence Is Still Insufficient

Despite its growing translational appeal, the current evidence base for TRIM47 remains insufficient for robust clinical implementation. The first limitation is clinical. Most available studies are retrospective, frequently single‐center, and based on relatively small or biologically heterogeneous cohorts. Assay platforms vary substantially, including differences in transcriptomic readouts, immunohistochemical methods, and cut‐off definitions for “high” versus “low” TRIM47 expression. As a result, the reproducibility, comparability, and incremental value of TRIM47 over existing clinical and molecular markers remain poorly defined. Even when TRIM47 appears within multigene prognostic or predictive models, its independent contribution is often difficult to isolate from the broader network context in which it is embedded [54].

A second limitation is mechanistic. Although a growing number of TRIM47‐associated substrates and signaling axes have been reported, many remain incompletely validated. For several putative targets, direct biochemical evidence of ubiquitin transfer, site mapping, linkage definition, and rescue with ubiquitination‐resistant mutants is still lacking. Similarly, the relative contribution of K48‐ versus K63‐linked ubiquitination is not fully resolved across disease settings, and structural understanding of how TRIM47 engages specific E2 enzymes or substrates remains limited. These gaps complicate efforts to distinguish between directly actionable TRIM47 circuitry and broader pathway associations in which TRIM47 may be only one participant among many [55, 56].

A third limitation concerns model systems and biological context. Much of the current literature relies on transient knockdown, overexpression, or acute injury models that do not fully recapitulate the chronic, heterogeneous, and multicellular nature of human disease. Organ‐ and cell type–specific in vivo models remain scarce, and the relative contributions of epithelial, stromal, endothelial, immune, and tumor cell compartments are still poorly defined. In parallel, many human omics studies that implicate TRIM47 are correlative and do not adequately disentangle its role from neighboring genes, co‐regulated ubiquitin pathway components, or disease‐associated transcriptional programs. Therefore, the main barrier to translation is not the absence of biological signal, but the gap between recurrent association and clinically actionable validation [57, 58, 59].

6.3. Druggability: Direct Versus Indirect Targeting

From a therapeutic perspective, TRIM47 is druggable in principle, but the practical routes to targeting it differ substantially in feasibility and risk. Direct targeting strategies would include small molecules that inhibit its E3 ligase activity, proteolysis‐targeting chimeras (PROTACs) that induce TRIM47 degradation, or interface‐disrupting agents that block TRIM47–substrate interactions. Conceptually, these approaches are attractive because they would act at the level of the pathogenic signaling organizer itself. However, no TRIM47‐selective inhibitor has yet progressed to meaningful preclinical development, and the lack of high‐resolution structural information further limits rational ligand design. At present, therefore, direct TRIM47 inhibition remains more a strategic objective than a near‐term translational option [60, 61].

Indirect targeting appears more immediately tractable. Upstream modulation could involve pathways known or suspected to regulate TRIM47 expression, such as inflammatory cytokine signaling, METTL3‐dependent m6A stabilization, or broader stress‐responsive transcriptional programs [19]. Downstream or counter‐regulatory modulation may, in some settings, be even more practical. Examples include restoration of PPM1A activity in pulmonary fibrosis, preservation of SIRT1‐dependent restraint in inflammatory injury, stabilization of CYLD‐linked signaling brakes, or metabolic interventions that lower TRIM47 expression. These approaches do not inhibit TRIM47 directly, but they may reverse or buffer TRIM47‐driven pathway imbalance in a context‐specific manner [14]. Such strategies may ultimately prove more feasible in the short term, particularly where TRIM47 biology converges on a limited number of recurrent pathway modules.

The major caveat is safety. TRIM47 participates in inflammatory signaling, stress responses, and antiviral regulation, raising the possibility that sustained suppression could alter host defense, immune homeostasis, or tissue repair. This issue is particularly relevant because the same TRIM47‐dependent circuitry that contributes to pathological inflammation or fibrosis may also help shape adaptive responses to injury or infection. Systematic toxicology studies are still lacking, and long‐term on‐target effects remain essentially undefined. At present, the most realistic translational path may lie not in immediate direct inhibition of TRIM47, but in mechanism‐informed indirect modulation combined with careful definition of therapeutic window, tissue context, and disease stage.

6.4. What the Field Most Urgently Needs Next

The next stage of TRIM47 research should move beyond further accumulation of associative disease links and instead prioritize a smaller number of substrate‐resolved, context‐specific, and clinically testable questions. A first priority is mechanistic resolution. The field needs rigorous validation of reported substrates, precise ubiquitination site and chain mapping, and broader structural and interactome studies that can clarify how TRIM47 selects partners in different cellular environments. Without this level of biochemical resolution, translational claims will remain difficult to rank or operationalize.

A second priority is context specificity. Cell type–restricted and organ‐specific models are essential to determine whether TRIM47 functions similarly in epithelial, stromal, endothelial, immune, and tumor compartments, or whether distinct substrates dominate in different tissues. This is particularly important for distinguishing beneficial versus harmful consequences of TRIM47 modulation, especially in diseases where inflammatory control and tissue repair coexist in dynamic balance. Integration of single‐cell, spatial, proteomic, ubiquitinomic, and metabolomic approaches will be especially valuable in this regard, as it may reveal which TRIM47 programs are shared across disease states and which are uniquely context dependent.

A third priority is clinical translation at an evidence standard appropriate for biomarker development. Prospective, multi‐center studies are needed to standardize assay methodology, define reproducible expression thresholds, and determine whether TRIM47 adds independent value beyond established clinicopathologic and molecular markers. This applies not only to prognosis, but also to treatment stratification, where claims regarding platinum resistance, PARP vulnerability, antifibrotic responsiveness, or dietary sensitivity remain promising but insufficiently validated.

A fourth priority is therapeutics. Whether TRIM47 is best targeted directly, indirectly, or through substrate‐opposing interventions will likely depend on disease context, target tractability, and safety window. Future drug‐development efforts should therefore be tightly linked to mechanistic biology rather than pursued in parallel. Progress in TRIM47 research will depend not only on identifying additional disease associations but on converting recurrent biological signal into substrate‐resolved, context‐specific, and clinically testable models of intervention.

7. Conclusion

TRIM47 has emerged as a recurrent E3 ubiquitin ligase at the intersection of inflammation, tissue injury, fibrosis, cancer progression, and treatment response. Rather than acting as a disease‐specific factor, TRIM47 is better understood as a context‐dependent organizer of ubiquitin signaling, in which substrate choice and ubiquitin‐chain topology converge on a limited number of shared pathogenic outputs. Through degradation of inhibitory or protective factors and activation of signaling mediators, TRIM47 promotes inflammatory amplification, maladaptive remodeling, metabolic adaptation, apoptosis escape, DNA‐repair rewiring, and context‐dependent therapeutic vulnerability.

This mechanism‐centered perspective helps unify the diverse disease settings in which TRIM47 has been implicated. In non‐neoplastic disorders, TRIM47 amplifies inflammatory injury and fibrotic progression by removing endogenous signaling brakes. In cancer, the same logic supports malignant fitness, invasive plasticity, and microenvironmental remodeling. Importantly, TRIM47 also behaves as a double‐edged regulator of therapy response: it can promote resistance to several treatments, yet in selected DNA repair‐deficient contexts, it may also create exploitable dependencies.

Although TRIM47 shows clear translational promise, major gaps remain between biological signal and clinical application. Substrate validation is incomplete, ubiquitin‐site and chain mapping remain limited, cell type–specific functions are insufficiently resolved, and no selective TRIM47‐targeted therapy has yet been established. Overall, TRIM47 should be regarded as a recurrent pathway‐rewiring ligase with broad pathogenic relevance and emerging translational potential. Future progress will depend on converting associative evidence into substrate‐resolved, context‐specific, and clinically testable models of intervention.

Author Contributions

J.M.: Writing – original draft, data curation, formal analysis. K.W.: writing – original draft, data curation, formal analysis. Y.Z.: writing – original draft, data curation, formal analysis. H.W.: writing – original draft. C.X.: writing – original draft. R.Y.: writing – original draft. L.Y.: writing – review and editing.

Funding

This work was supported by the National Natural Science Foundation of China (Grant No. 82560153), Special funds for guiding local science and technology development from the central government (Project No. 24ZYQA050), the Youth Science and Technology Fund Program of Gansu Province (Grant No. 22JR5RA1018), and the Science and Technology Planning Project of Lanzhou City (Grant No. 2023‐4‐39).

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.